Nicotinuric acid: A potential marker of metabolic syndrome through a metabolomics-based approach

Diabetes Care

Volumn 36, Issue 6, 2013, Pages 1729-1731

  Huang, Chun Feng ^a,b,c   Cheng, Mei Ling ^d   Fan, Chun Ming ^d   Hong, Chuang Ye ^a,e   Shiao, Ming Shi ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Saint Mary's Hospital   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINURIC ACID; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE MARKER; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; METABOLIC SYNDROME X; METABOLITE; METABOLOMICS; OBESITY; PROTEIN BLOOD LEVEL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TIME OF FLIGHT MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; METABOLOMICS; MIDDLE AGED; NICOTINIC ACIDS;

EID: 84874632047     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1067     Document Type: Article

References (14)

1. Chen KH, Cheng ML, Jing YH, Chiu DT, Shiao MS, Chen JK. Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2011;301:E853-E863
2. Inamadugu JK, Damaramadugu R, Mullangi R, Ponneri V. Simultaneous determination of niacin and itsmetabolitesdnicotinamide, nicotinuric acid and N-methyl-2-pyridone- 5-carboxamidedin human plasma by LCMS/ MS and its application to a human pharmacokinetic study. Biomed Chromatogr 2010;24:1059-1074
3. Jones KM. The mechanism of nicotinuric acid synthesis. Biochem J 1959;73:714-719
4. Rinaldo P, Schmidt-Sommerfeld E, Posca AP, Heales SJ, Woolf DA, Leonard JV. Effect of treatment with glycine and Lcarnitine in medium-chain acyl-coenzyme A dehydrogenase de ficiency. J Pediatr 1993;122:580-584 (Pubitemid 23093583)
5. Ellis BA, Poynten A, Lowy AJ, et al. Longchain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 2000;279:E554-E560
6. Zhu J, Ganton MD, Kerr MA, Workentin MS. Chemicalmodification of monolayer-protected gold nanoparticles using hyperbaric conditions. J Am Chem Soc 2007;129:4904-4905 (Pubitemid 46651365)
7. Fukui M, Tanaka M, Toda H, et al. High plasma 5-hydroxyindole-3-acetic acid concentrations in subjects with metabolic syndrome. Diabetes Care 2012;35:163-167
8. Seubert W, Podack ER. Mechanisms and physiological roles of fatty acid chain elongation in microsomes and mitochondria. Mol Cell Biochem 1973;1:29-40
9. Rawlings BJ. Biosynthesis of fatty acids and related metabolites. Nat Prod Rep 1998;15:275-308 (Pubitemid 28295389)
10. Villines TC, Kim AS, Gore RS, Taylor AJ. Niacin: the evidence, clinical use, and future directions. Curr Atheroscler Rep 2012;14:49-59
11. Karpe F, Frayn KN. The nicotinic acid receptorda new mechanism for an old drug. Lancet 2004;363:1892-1894 (Pubitemid 38748647)
12. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63
13. Danne O, Lueders C, Storm C, Frei U, Möckel M. Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. Clin Chim Acta 2007;383:103-109 (Pubitemid 47018253)
14. Landfald B, Strøm AR. Choline-glycine betaine pathway confers a high level of osmotic tolerance in Escherichia coli. J Bacteriol 1986;165:849-855 (Pubitemid 16071415)